231 related articles for article (PubMed ID: 11509959)
1. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism.
Steitz J; Brück J; Knop J; Tüting T
Gene Ther; 2001 Aug; 8(16):1255-63. PubMed ID: 11509959
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
[TBL] [Abstract][Full Text] [Related]
3. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
Tan XH; Liu C; Wan YH
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
[TBL] [Abstract][Full Text] [Related]
4. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury].
Tan XH; Wan YH
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1596-600. PubMed ID: 16185524
[TBL] [Abstract][Full Text] [Related]
5. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
6. Altered intracellular sorting signals do not influence the efficacy of genetic melanoma vaccines incorporating helper determinants in mice.
Brück J; Steitz J; Strand D; Tüting T
J Gene Med; 2005 May; 7(5):613-20. PubMed ID: 15580620
[TBL] [Abstract][Full Text] [Related]
7. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells.
Wan Y; Emtage P; Zhu Q; Foley R; Pilon A; Roberts B; Gauldie J
Cell Immunol; 1999 Dec; 198(2):131-8. PubMed ID: 10648127
[TBL] [Abstract][Full Text] [Related]
8. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma.
Shibagaki N; Udey MC
Eur J Immunol; 2003 Apr; 33(4):850-60. PubMed ID: 12672050
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
[TBL] [Abstract][Full Text] [Related]
11. Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity.
Steitz J; Brück J; Gambotto A; Knop J; Tüting T
Gene Ther; 2002 Feb; 9(3):208-13. PubMed ID: 11859424
[TBL] [Abstract][Full Text] [Related]
12. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
13. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
14. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
15. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12.
Chen Y; Emtage P; Zhu Q; Foley R; Muller W; Hitt M; Gauldie J; Wan Y
Gene Ther; 2001 Feb; 8(4):316-23. PubMed ID: 11313806
[TBL] [Abstract][Full Text] [Related]
16. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination.
Steitz J; Tormo D; Schweichel D; Tüting T
Cancer Gene Ther; 2006 Mar; 13(3):318-25. PubMed ID: 16151477
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
Tormo D; Ferrer A; Bosch P; Gaffal E; Basner-Tschakarjan E; Wenzel J; Tüting T
Cancer Res; 2006 May; 66(10):5427-35. PubMed ID: 16707471
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma.
Hirschowitz EA; Leonard S; Song W; Ferris B; Leopold PL; Lewis JJ; Bowne WB; Wang S; Houghton AN; Crystal RG
Gene Ther; 1998 Jul; 5(7):975-83. PubMed ID: 9813669
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
[TBL] [Abstract][Full Text] [Related]
20. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
